The Effect of Intra-Articular Injection of RegenoGel-OSP™(Self-Plasma) to Treat Pain Following Arthroscopic Surgery

Inclusion Criteria: * Subject has signed and dated the informed consent form. * Subject is a male or female over the age of 45. * Patients scheduled for knee arthroscopic surgery due to degenerative or traumatic meniscal tear. Exclusion Criteria: * Subject had any intra-articular injections to the intended study knee within 3 months prior to Screening. * Subject is unable to stop chronic administration of pain medications (including paracetamol), from the day before each study visit through completion of the study visit. * Subject has a history of Psoriatic Arthritis, Rheumatoid Arthritis,or any other inflammatory condition associated with arthritis. * Subject has a superficial wound in the area of the intended study knee. * Subject is scheduled for knee ligaments reconstructive surgery. * Subject has fever signs or symptoms of systemic infection or infection of the intended study knee. * Subject has known sensitivity to any of the treatment components, egg, rubber or latex. * Subject has a history of anaphylactic shock or other severe systemic response or other adverse event to human blood products. * Subject has a clinically significant abnormal finding (e.g., laboratory result or ECG). * Subject has known Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS), Hepatitis B or C viral infections, or acute or chronic liver disease. * Subject has ever had cellulitis of the lower extremities, a superficial or deep vein thrombosis, or a family history of a clotting disorders. * Subject receives any investigational device or product within 30 days of Visit l. * Subject is receiving an oral or injected anticoagulant. * Subject ever abused drugs or alcohol (self-reported).